The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Domestic market and developing countries will need doses of Indian vaccines
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
CDSCO to fast-track trials and approval for COVID19 vaccine
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers
The govt has rolled out three schemes for promoting the manufacture of API
Subscribe To Our Newsletter & Stay Updated
